The results show 70% (n = 7) of patients responded, including 30% (n = 3) who achieved clinical remission. The study represents a step up from previous research that showed the treatment was effective in treating patients with mild-moderate and moderate-severe ulcerative colitis. The 2 part trial included a 4 week open-label study and a placebo-controlled trial at 2 centers in Israel and Greece. In the multi-center controlled trial, investigators from Israel found the promising results by week 8 for the treatment called CurQD and also found curcumin alone for an additional 8 weeks maintained the response for the majority of patients with no new safety signals. New data presented during Crohn’s and Colitis Congress 2023 in Denver suggest an herbal compound curcumin and QingDai outperformed placebo to induce clinical response and remission in patients with ulcerative colitis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |